Company intelligence / Profile preview

STB INN

Gothenburg, Swedenstrandbackamedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

STB INN is developing PERIsign, a novel medical device designed to revolutionize the assessment of patients with abdominal pain by detecting peritonitis—a physiological response to severe intraabdominal illness. The company aims to improve diagnostic accuracy and patient outcomes in emergency and acute care settings. No clinical trial results or commercial launch data are currently available.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Device (Medical device)
Industry: Physiological Monitoring

Beyond the preview

Go deeper on STB INN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STB INN.

Explore the full profile